In a significant milestone for Alzheimer’s disease treatment, the U.S. Food and Drug Administration (FDA) recently approved the groundbreaking new drug, Leqembi. The medication is poised to bring new hope and treatment options to the more than 55 million people worldwide currently diagnosed with dementia or Alzheimer’s. To better understand Leqembi’s potential impacts, let’s unpack […]
Read more
The Centers for Medicare and Medicaid Services (CMS) have taken significant steps to improve cognitive care for Medicare beneficiaries. In fact, detecting cognitive impairment is a required element of annual wellness visits (AWV). However, many healthcare providers struggle to implement effective and efficient cognitive screening strategies, resulting in missed opportunities for early detection and care. […]
Read more
With almost 50 million people worldwide affected by dementia—and Alzheimer’s disease the likely cause in 60% to 80% of these cases—detection and care is at a critical juncture. Despite high prevalence of cognitive disease, significant barriers, healthcare provider burnout, and systemic bottlenecks all interfere with their identification and treatment. By exploring common problems in cognitive […]
Read more